Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Generate Biomedicines, Inc.
13G
GENB · 370920100
|
48.9% |
5/15/2026
Event 3/31/2026
|
|||
| Flagship Pioneering Fund VI, L.P. | 9.9% | ||||
| Flagship Pioneering Fund VI General Partner LLC | 9.9% | ||||
| Pioneering Medicines 02, LLC | 1.2% | ||||
| Flagship Pioneering Fund VII, L.P. | 13.1% | ||||
| Flagship Pioneering Fund VII General Partner LLC | 13.1% | ||||
| Nutritional Health LTP Fund, L.P. | 0.8% | ||||
| Nutritional Health LTP Fund General Partner LLC | 0.8% | ||||
| Flagship Pioneering Special Opportunities Fund II, L.P. | 2.2% | ||||
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | 2.2% | ||||
| FPN II, L.P. | 3.4% | ||||
| FPN General Partner LLC | 3.4% | ||||
| Flagship VentureLabs VI, LLC | 19.5% | ||||
| Flagship VentureLabs VI Manager LLC | 19.5% | ||||
| Flagship Pioneering, LLC | 48.9% | ||||
| Afeyan Noubar | 48.9% | ||||